Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Condition:   Merkel Cell Carcinoma Intervention:   Drug: Pembrolizumab Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials